Search results: Found 2

Listing 1 - 2 of 2
Sort by
Galeni In Hippocratis Epidemiarum librum I commentariorum I-III versio Arabica / Galen. Commentary on Hippocrates' Epidemics Book I

Author:
Book Series: Corpus Medicorum Graecorum – Supplementum Orientale ISBN: 9783110405835 9783110406597 9783110406771 Year: Volume: 1 Pages: 736 DOI: 10.26530/OAPEN_531190 Language: English
Publisher: De Gruyter Grant: Wellcome Trust - 084192MA
Subject: Medicine (General)
Added to DOAB on : 2015-06-29 09:34:24
License:

Loading...
Export citation

Choose an application

Abstract

The present volume offers the first critical edition of Book 1 of the medieval Arabic translation of Galen's Commentary on the Hippocratic Epidemics, produced by the celebrated translator Hunayn ibn Ishāq (d. ca. 870). The edition is based on all extant Arabic textual witnesses, including the Arabic secondary transmission. The translation of Galen's commentary became a crucial source for the development of medicine in the Islamic world, especially in the nascent field of clinical medicine. It was frequently read and quoted in later Arabic medical literature, and several Arabic authors used it to produce a wide range of didactic writings for medical students and practising physicians. The English translation, which aims to convey some of the flavour of the Arabic translation, comes with extensive notes on the differences between the Greek original and the Arabic translation. A thorough comparison between the two versions of the commentary provides important insights into the translation style and technique of Hunayn ibn Ishāq and his circle and Arabic medical terminology at the time.

Targeting PI3K/mTOR signaling in cancer

Author:
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889192441 Year: Pages: 93 DOI: 10.3389/978-2-88919-244-1 Language: English
Publisher: Frontiers Media SA
Subject: Science (General) --- Biology --- Medicine (General) --- Oncology
Added to DOAB on : 2015-11-16 15:44:59
License:

Loading...
Export citation

Choose an application

Abstract

The phosphatidylinositol 3-kinase (PI3K)/mTOR pathway integrates signals from growth factors with nutrient signals and other conditions and controls multiple cell responses, including proliferation, survival and metabolism. Deregulation of the PI3K pathway has been extensively investigated in connection to cancer. Somatic or inherited mutations frequently occur in tumor suppressor genes (PTEN, TSC1/2, LKB1) and oncogenes (PIK3CA, PIK3R1, AKT) in the PI3K/mTOR pathway. The fact that the PI3K/mTOR pathway is deregulated in a large number of human malignancies, and its importance for different cellular responses, makes it an attractive drug target. Pharmacological PI3K inhibitors have played a very important role in studying cellular responses involving these enzymes. Currently, a wide range of selective PI3K inhibitors have been tested in preclinical studies and some have entered clinical trials in oncology. Rapamycin and its analogs targeting mTOR are effective in many preclinical cancer models. Although rapalogs are approved for the treatment of some cancers, their efficacy in clinical trials remains the subject of debate. Due to the complexity of the PI3K/mTOR signaling pathway, developing an effective anti-cancer therapy remains a challenge. The biggest challenge in curing cancer patients with various signaling pathway abnormalities is to target multiple components of different signal transduction pathways with mechanism-based combinatorial treatments.

Listing 1 - 2 of 2
Sort by
Narrow your search

Publisher

De Gruyter (1)

Frontiers Media SA (1)


License

CC by (1)

CC by-nc-nd (1)


Language

english (2)


Year
From To Submit

2014 (2)